Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | ESR1 | P03372 | 5/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.44 |
| ▸ | LTA4H | P09960 | 2/20 | 0.44 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 3/20 | 0.44 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.42 |
| ▸ | THRA | P10827 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL805440 | 0.85 | MAOB (0.45) | MEN1NPC1ALDH1A1GAAMAPT | |
| SCHEMBL802622 | 0.82 | MAOB (0.57) | MEN1NPC1ALDH1A1GAAMAPT | |
| SCHEMBL803144 | 0.81 | MAOB (0.66) | NPC1ALDH1A1MAPTRAB9AMAOB | |
| SCHEMBL805443 | 0.78 | MAOB (0.44) | MEN1NPC1ALDH1A1GAAMAPT | |
| SCHEMBL30577530 | 0.78 | MAOA (0.49) | ALDH1A1MAPTRAB9AESR1ESR2 | |
| SCHEMBL802750 | 0.78 | MAOA (0.49) | ALDH1A1MAPTRAB9AESR1ESR2 | |
| SCHEMBL19310351 | 0.77 | ROCK2 (0.59) | AAK1 | |
| SCHEMBL8385525 | 0.77 | MEN1 (0.59) | MEN1NPC1ALDH1A1GAAMAPT | |
| SCHEMBL26768220 | 0.74 | MAOB (0.42) | MEN1ALDH1A1MAPTRAB9AKMT2A | |
| SCHEMBL13264370 | 0.73 | MAOB (0.69) | MEN1NPC1ALDH1A1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096795-B2 | Liquid crystal display | MERCK PATENT GMBH (DE) | 2015-08-04 | — | — | US | disclosed |
| EP-2432851-B1 | LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2013-10-02 | — | — | EP | disclosed |
| US-20120069289-A1 | LIQUID CRYSTAL DISPLAY | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-03-22 | — | — | US | disclosed |
| WO-2010133278-A1 | LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120069289-A1 | LIQUID CRYSTAL DISPLAY | LPXN, VCL, ACP3 | MEN1 2525/4885NPC1 4142/4885ALDH1A1 3543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.